Group 1 - The company has been included in multiple indices, such as the Hang Seng Composite Index (HSCI), Hang Seng Hong Kong Stock Connect Index, and Hang Seng Innovative Drug Index, effective March 9, 2026 [1] - The inclusion in the MSCI Global Small Cap Index will take effect after the market closes on February 27, 2026, reflecting the company's growing recognition in the market [1] - The Hang Seng Composite Index covers the top 95% of companies listed on the Hong Kong Stock Exchange, making it a significant benchmark for index funds and performance evaluation [1] Group 2 - The company will also be included in various other Hang Seng indices, such as the Hang Seng Composite Small Cap Index and the Hang Seng Healthcare Index, indicating broad market acceptance [2] - The board believes that inclusion in these important indices demonstrates investor recognition of the company's value and growth potential, which is expected to enhance stock liquidity and diversify the shareholder base [2] - The company aims to strengthen its leading position in the RAS sector and enhance its international competitiveness in innovative drug fields, driving value creation through its R&D advantages [2]
劲方医药-B获纳入恒生指数系列及MSCI指数成份股